statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How Is The Market Feeling About Intra-Cellular Therapies?

Futures Rebound On Strong Earnings Even As Global Market Mood Remains Dismal

Futures Rebound On Strong Earnings Even As Global Market Mood Remains Dismal

 S&P futures traded modestly in the green, erasing earlier losses and signaling a recovery after the S&P 500...

Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL Research Report), Paragon 28...

Intra-Cellular Therapies: A Strong Buy on Patent Defense and Promising Clinical Prospects

Analyst Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Intra-Cellular Therapies (ITCI Research Report) and keeping the price...

8 Analysts Assess Intra-Cellular Therapies: What You Need To Know

Latest Ratings for ITCI
 DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsOutperform Feb 2022NeedhamMaintainsBuy Feb 2022Goldman SachsInitiates Coverage OnBuy
 View More Analyst Ratings for...

Intra-Cellular Therapies (ITCI, $68.23) price exceeded its 50-day Moving Average on April 01, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Noteworthy Thursday Option Activity: ITCI, FSLR, EXAS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intra-Cellular Therapies Inc (ITCI), where a total of 8,817 contracts have traded so far...

Intra-Cellular Therapies (ITCI, $67.97) price exceeded its 50-day Moving Average on March 25, 2024

Intra-Cellular Therapies (ITCI, $68.45) price may drop as it broke higher Bollinger Band on Mar 21, 2024

This price move could be a signal that ITCI may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Intra-Cellular Therapies (ITCI, $68.45) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 21, 2024

This is a Bullish indicator signaling ITCI's price could rise from here. Traders may explore going long the stock or buying call options...

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Volume	625,487.00
52-Wk High	$84.89
52-Wk Low	$45.50

ITCI Intra-Cellular Therapies Inc

About

Feed

News

Sentiment

Earnings

Fundamentals